FLAG is a chemotherapy regimen used for relapsed and refractory acute myeloid leukemia (AML).
There are several intensified versions of the FLAG regimen in which a third chemotherapeutic agent is added.
In the FLAG-IDA regimen (also called FLAG-Ida, IDA-FLAG, or Ida-FLAG), idarubicin—an anthracycline antibiotic that is able to intercalate DNA and prevent cell division (mitosis)[2][3][4]—is added to the standard FLAG regimen.
Mitoxantrone is a synthetic anthracycline analogue (an anthracenedione) that, like idarubicin, can intercalate DNA and prevent cell division.
[7][8][9][10][11][12][13] The FLAMSA protocol is most often used as an induction part of a reduced-intensity conditioning regimen for patients eligible to undergo an allogeneic stem cell transplant.